Heat Biologics Stock Price

0.12 (3.04%)
Upgrade to Real-Time
Afterhours (Closed)
Volume 383,999
Bid Price 4.08
Ask Price 4.14
News -
Day High 4.21


52 Week Range


Day Low 3.95
Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
Canadian Level 1 + USA
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Heat Biologics Inc HTBX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.12 3.04% 4.07 19:58:44
Open Price Low Price High Price Close Price Prev Close
3.97 3.95 4.21 4.10 3.95
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,337 383,999 $ 4.12 $ 1,583,461 - 3.76 - 17.00
Last Trade Time Type Quantity Stock Price Currency
19:58:44 formt 100 $ 4.07 USD


Draw Mode:

Heat Biologics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 103.39M 25.40M 24.32M $ 2.95M $ - -1.76 -3.60
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - 8.80%

more financials information »

Heat Biologics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical HTBX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week4.354.73863.764.21348,688-0.28-6.44%
1 Month5.305.393.764.60292,361-1.23-23.21%
3 Months6.266.393.765.32241,449-2.19-34.98%
6 Months6.5110.853.767.80589,760-2.44-37.48%
1 Year7.3517.003.768.721,194,114-3.28-44.63%
3 Years9.4530.101.267710.325,365,726-5.38-56.93%
5 Years85.4087.501.267712.523,540,813-81.33-95.23%

Heat Biologics Description

Heat Biologics Inc is an immuno-oncology company. It is engaged in developing therapies that activate a patient's immune system against cancer utilizing an engineered form of gp96. The group's T cell-stimulating therapeutic vaccine platform technologies, Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT) form the basis of its product candidates. Through ImPACT, it developed product candidates consisting of live, genetically modified, irradiated human cancer cells that secrete tumour-associated antigens together with an immune response stimulator called gp96. Through ComPACT, the firm engineered product candidates that incorporate ligand fusion proteins targeting co-stimulatory receptors into the gp96-Ig expression vector.
Your Recent History
Heat Biolo..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20211208 04:46:37